LQDA Liquidia Corporation
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
49.43
P/S
18.82
EV/EBITDA
103.51
DCF Value
$-98.78
FCF Yield
0.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.8%
Operating Margin
15.8%
Net Margin
7.7%
ROE
46.8%
ROA
5.6%
ROIC
12.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $132.9M | $52.9M | $— |
| Q4 null | $92.0M | $14.6M | $— |
| FY null | $158.3M | $-68.9M | $— |
| Q3 null | $54.3M | $-3.5M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$63.00
Target (Median)
$62.00
Target Range
$60.00 - $67.00
Trading Activity
Insider Trades
View AllRelated AI Research
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.42
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.